Cargando…
Use of analgesics in France, following dextropropoxyphene withdrawal
BACKGROUND: In 2009, the European Medicines Agency recommended withdrawal of dextropropoxyphene (DXP); in March 2011 it was withdrawn from the market in France. Up until that time the combination dextropropoxyphene-paracetamol (DXP/PC) was widely used for analgesia. At withdrawal, French regulators...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880096/ https://www.ncbi.nlm.nih.gov/pubmed/29609613 http://dx.doi.org/10.1186/s12913-018-3058-1 |
_version_ | 1783311115603673088 |
---|---|
author | Van Ganse, E. Belhassen, M. Ginoux, M. Chrétien, E. Cornu, C. Ecoffey, C. Aubrun, F. |
author_facet | Van Ganse, E. Belhassen, M. Ginoux, M. Chrétien, E. Cornu, C. Ecoffey, C. Aubrun, F. |
author_sort | Van Ganse, E. |
collection | PubMed |
description | BACKGROUND: In 2009, the European Medicines Agency recommended withdrawal of dextropropoxyphene (DXP); in March 2011 it was withdrawn from the market in France. Up until that time the combination dextropropoxyphene-paracetamol (DXP/PC) was widely used for analgesia. At withdrawal, French regulators recommended that DXP/PC be replaced by other step 2 analgesics, i.e. tramadol, codeine, or opium-containing drugs, or by PC for a weak level of pain. To investigate prescribing behaviours after DXP/PC withdrawal, dispensations of analgesics before and after withdrawal were analysed. METHODS: Aggregated dispensation data of analgesics prescribed between January 2009 and December 2012 in the Rhône-Alpes region were obtained from the general health insurance claims data; changes in analgesic dispensation over time were analysed with the ATC/DDD methodology. Pre (Jan-June 2009) and post-withdrawal (Jan-June 2012) changes of DDDs where computed for each analgesic step. RESULTS: The dispensations of DXP/PC experienced a two-step decrease until 2011. Over the withdrawal period 2009-2012, there was a 14% decrease in the overall use of analgesic (from 109 to 94 DDDs), while the use of step 2 analgesics declined by 46% (− 22 DDDs, from 47 to 25 DDDs). This latter decline included a cessation of use of DXP/PC (29 DDDs in 2009) that were only in part (+ 7 DDDs, from 18 to 25 DDDs) compensated by increased use of codeine, tramadol and opium, in monotherapy or combined with PC. For step 1 analgesics, use increased with 9%, mostly PC (+ 8 DDDs, from 31 to 39 DDDs). Step 3 analgesics dispensations remained largely unchanged over this period (around 3 DDDs). CONCLUSIONS: In the Rhône-Alpes region, DXP/PC withdrawal was accompanied in part by an increased use of same level analgesics, and in part by an increased use of PC in monotherapy. The extent of DXP/PC use before withdrawal, and the increased use of PC after DXP withdrawal, underline the complexity of pain management. |
format | Online Article Text |
id | pubmed-5880096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58800962018-04-04 Use of analgesics in France, following dextropropoxyphene withdrawal Van Ganse, E. Belhassen, M. Ginoux, M. Chrétien, E. Cornu, C. Ecoffey, C. Aubrun, F. BMC Health Serv Res Research Article BACKGROUND: In 2009, the European Medicines Agency recommended withdrawal of dextropropoxyphene (DXP); in March 2011 it was withdrawn from the market in France. Up until that time the combination dextropropoxyphene-paracetamol (DXP/PC) was widely used for analgesia. At withdrawal, French regulators recommended that DXP/PC be replaced by other step 2 analgesics, i.e. tramadol, codeine, or opium-containing drugs, or by PC for a weak level of pain. To investigate prescribing behaviours after DXP/PC withdrawal, dispensations of analgesics before and after withdrawal were analysed. METHODS: Aggregated dispensation data of analgesics prescribed between January 2009 and December 2012 in the Rhône-Alpes region were obtained from the general health insurance claims data; changes in analgesic dispensation over time were analysed with the ATC/DDD methodology. Pre (Jan-June 2009) and post-withdrawal (Jan-June 2012) changes of DDDs where computed for each analgesic step. RESULTS: The dispensations of DXP/PC experienced a two-step decrease until 2011. Over the withdrawal period 2009-2012, there was a 14% decrease in the overall use of analgesic (from 109 to 94 DDDs), while the use of step 2 analgesics declined by 46% (− 22 DDDs, from 47 to 25 DDDs). This latter decline included a cessation of use of DXP/PC (29 DDDs in 2009) that were only in part (+ 7 DDDs, from 18 to 25 DDDs) compensated by increased use of codeine, tramadol and opium, in monotherapy or combined with PC. For step 1 analgesics, use increased with 9%, mostly PC (+ 8 DDDs, from 31 to 39 DDDs). Step 3 analgesics dispensations remained largely unchanged over this period (around 3 DDDs). CONCLUSIONS: In the Rhône-Alpes region, DXP/PC withdrawal was accompanied in part by an increased use of same level analgesics, and in part by an increased use of PC in monotherapy. The extent of DXP/PC use before withdrawal, and the increased use of PC after DXP withdrawal, underline the complexity of pain management. BioMed Central 2018-04-02 /pmc/articles/PMC5880096/ /pubmed/29609613 http://dx.doi.org/10.1186/s12913-018-3058-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Van Ganse, E. Belhassen, M. Ginoux, M. Chrétien, E. Cornu, C. Ecoffey, C. Aubrun, F. Use of analgesics in France, following dextropropoxyphene withdrawal |
title | Use of analgesics in France, following dextropropoxyphene withdrawal |
title_full | Use of analgesics in France, following dextropropoxyphene withdrawal |
title_fullStr | Use of analgesics in France, following dextropropoxyphene withdrawal |
title_full_unstemmed | Use of analgesics in France, following dextropropoxyphene withdrawal |
title_short | Use of analgesics in France, following dextropropoxyphene withdrawal |
title_sort | use of analgesics in france, following dextropropoxyphene withdrawal |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880096/ https://www.ncbi.nlm.nih.gov/pubmed/29609613 http://dx.doi.org/10.1186/s12913-018-3058-1 |
work_keys_str_mv | AT vangansee useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal AT belhassenm useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal AT ginouxm useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal AT chretiene useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal AT cornuc useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal AT ecoffeyc useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal AT aubrunf useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal |